Drying of Opzelura® (Ruxolitinib) Cream 1.5%: Implications for Clinical and Real-World Use
Main Article Content
Keywords
JAK, Janus Kinase, ruxolitinib
Abstract
References
1. Persaud I, et al. Int J Pharm. 2020;590:119889
2. Bissonnette R, et al. Rapid, Substantial, and Sustained Reduction of Itch in Adults With Atopic Dermatitis Applying Ruxolitinib Cream: Clinical and Translational Results From the Open-Label Phase 2 SCRATCH-AD Study. Presented at: European Academy of Dermatology and Venereology Congress; October 11-14, 2023; Berlin, Germany
2. Bissonnette R, et al. Rapid, Substantial, and Sustained Reduction of Itch in Adults With Atopic Dermatitis Applying Ruxolitinib Cream: Clinical and Translational Results From the Open-Label Phase 2 SCRATCH-AD Study. Presented at: European Academy of Dermatology and Venereology Congress; October 11-14, 2023; Berlin, Germany